APA (7th ed.) Citation

R, F., Y, W., I, R., E, B., S, S., ND, N., . . . H, X. (2026). Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer. BioRxiv : the preprint server for biology. https://doi.org/10.64898/2026.04.16.719008

Chicago Style (17th ed.) Citation

R, Fu, et al. "Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-null Non-small Cell Lung Cancer." BioRxiv : The Preprint Server for Biology 2026. https://doi.org/10.64898/2026.04.16.719008.

MLA (9th ed.) Citation

R, Fu, et al. "Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-null Non-small Cell Lung Cancer." BioRxiv : The Preprint Server for Biology, 2026, https://doi.org/10.64898/2026.04.16.719008.